Key takeaways
- The plant is predicted to produce 100 gigawatt hours (GWh) of renewable fuel yearly to AstraZeneca’s crops within the U.Ok.
- It was constructed by Future Biogas with a 15-year, $130 million offtake settlement from AstraZeneca.
- It operates with out subsidies and makes use of devoted vitality crops, not waste supplies.
In an business higher recognized for pioneering new medicines than renewable vitality, AstraZeneca has taken a big step: it’s now fuelling its U.Ok. operations with “inexperienced fuel” from a purpose-built biomethane plant.
The power, positioned at Gonerby Moor in Lincolnshire, east England, and operated by Future Biogas, is the UK’s first unsubsidised biomethane plant devoted to serving the life sciences sector.
It additionally represents a critical dedication to decarbonization — and a template for different high-emitting industries to comply with.
“We’ve been on a journey within the UK for a few years to cut back our carbon footprint,” Liz Chatwin, vice chairman of sustainability and international security, well being and surroundings at AstraZeneca, instructed Trellis. “The lacking piece of the puzzle was our supply of warmth energy.”
That hole has now been crammed by biomethane produced from regionally grown vitality crops via anaerobic digestion, then injected into the nationwide fuel grid. Biomethane is taken into account carbon impartial as a result of the carbon launched throughout digestion and burning is first absorbed by the crops as they develop.
The plant is predicted to produce 100 gigawatt hours (GWh) of renewable fuel yearly to AstraZeneca’s websites in Macclesfield, Cambridge, Luton and Speke — sufficient to satisfy the warmth demand of over 8,000 UK houses.
The plant, constructed with a 15-year, £100 million ($130 million) dedication from the pharmaceutical big, completes AstraZeneca’s objective of getting all its UK R&D and manufacturing powered by 100% renewable vitality. AstraZeneca will take all the plant’s era capability for not less than the subsequent 15 years.
Why biomethane is an efficient match for the life sciences
The pharmaceutical business has an enormous emissions downside. In line with a 2019 research, pharma firms generate over 48 tonnes of CO₂ equal per $1 million of income — round 55 p.c greater than the emissions depth of the automotive sector.
In all, roughly 4.5 p.c of world emissions are attributed to the healthcare sector, with the majority of those attributed to pharmaceutical procurement, manufacturing and use.

So why flip to biomethane?
“There’s a variety of processes in prescribed drugs which are laborious to affect as a result of they require excessive warmth, like elevating steam,” mentioned Philipp Lukas, CEO of Future Biogas. “Biomethane is a drop-in gasoline for that. It’s a one-for-one substitute, that means all of the infrastructure to ship and use it’s already there.
“If an organization desires to decarbonize shortly while on that journey to electrification, then working on biomethane can present an answer in 12 to 18 months.”
Future-proof energy provides
Past comfort, the venture additionally goals to be self-sustaining. In contrast to many earlier biogas schemes, this plant operates with out subsidies and makes use of devoted vitality crops — not waste supplies.
That distinction issues. Whereas animal manure generally is a worthwhile feedstock for biomethane, Lukas famous it comes with the complication of probably selling intensive livestock farming. “AstraZeneca wished one thing the place they might see the sustainability all over,” he mentioned.
As a substitute, crops are grown regionally below five-year contracts that assist farmers put money into regenerative practices, reminiscent of diversified crop rotation, diminished fertilizer use and improved soil well being.
“The thrilling factor about that is that you would be able to help meals manufacturing, not solely boosting resilience but in addition lowering fossil gasoline inputs on the farm,” Lukas mentioned.
Lower carbon, and seize it too
The Gonerby Moor website doesn’t cease at producing biomethane: It additionally contains carbon seize know-how that removes CO₂ from the fermentation course of — CO₂ that the vitality crops had absorbed from the environment a season earlier.
To start with, the captured fuel might be utilized in business — for greenhouses, gentle drink carbonization and the like – however longer-term, AstraZeneca hopes to ship it for everlasting geological storage via Norway’s Northern Lights venture, turning the plant right into a carbon-negative operation.
In line with AstraZeneca, the partnership with Future Biogas will scale back its emissions by 20,000 tonnes of CO₂ equal per yr. A significant retrofit of its Macclesfield mixed warmth and energy (CHP) plant will save one other 16,000 tonnes.
All that is a part of the corporate’s Ambition Zero Carbon programme, which goals to halve emissions throughout its full worth chain by 2030 and attain science-based web zero by 2045.
A mannequin for others?
It’s a daring transfer — however is it replicable? Might different pharmaceutical or life science firms undertake the same strategy?
“The Moor Bioenergy plant serves as a wonderful blueprint for different firms in our sector.” mentioned Chatwin. “By using regionally sourced bioenergy crops and revolutionary carbon seize applied sciences, we’re demonstrating how vitality effectivity and sustainability might be built-in into manufacturing and analysis processes.”
“The unsubsidized nature of this venture highlights the broader position of companies in serving to to construct up renewable vitality infrastructure,” mentioned Amy Sales space, a researcher on the College of Oxford who research the environmental influence of well being methods. “It could be good to see others within the business taking that up too.”
AstraZeneca shouldn’t be solely shopping for into biomethane — it has additionally minimize its vitality demand. The unique estimate was that the corporate would want 350 GWh of electrical energy per yr. After a company-wide push on vitality effectivity — upgrading gear, bettering insulation and switching to electrical methods the place attainable — that determine dropped to 100 GWh.
“At all times comply with the maxim: use much less, and pay extra,” mentioned Lukas. “The much less vitality you want, the extra you possibly can afford to put money into the sustainable choices.”
The corporate is planning to put money into different renewable vitality tasks, together with a partnership within the US with Vanguard Reneawables to ship biomethane to all of its websites by the tip of 2026.
Different firms are additionally exploring biomethane. French pharmaceutical firm Sanofi just lately introduced a purchase order settlement to decarbonize 56 p.c of its fuel consumption in France. The 6-year deal covers 1.3 TWh of energy, together with an extra 10-year contract protecting 110 GWh to decarbonize Sanofi’s website in Lyon.
GSK, one other pharmaceutical behemoth, is as a substitute trying to photo voltaic. The corporate agreed a digital energy buy settlement in 2024 to produce 50 p.c of its European operations with solar energy for 12 years utilizing websites in Spain.
Challenges forward
Power procurement alone is not going to considerably shrink AstraZeneca’s footprint. Upwards of 90 p.c of the pharmaceutical business’s emissions are Scope 3, stemming from advanced, international provide chains that embody the whole lot from packaging and logistics to the tip use of merchandise, all working below various rules throughout completely different nations.
“I might congratulate [AstraZeneca] on this, however to place it into perspective, Scope 2 is a small a part of the general emissions problem,” mentioned Dr. Jagjit Singh Srai, head of the Centre for Worldwide Manufacturing on the College of Cambridge. “Scope 1 is one thing you possibly can actually management — that’s your vitality effectivity, et cetera. And I feel the subsequent most controllable component is your vitality sourcing. They are going to be Scope 3 additionally and addressing that straight.”
AstraZeneca has its eyes upon the Scope 3 problem, as nicely.
Greater than two thirds of Astra Zeneca’s suppliers have dedicated to science-based targets, Chatwin mentioned. The corporate can also be a founding member of Energize — a collaboration between Schneider Electrical and 19 international pharma firms to “facilitate renewable energy at scale for our suppliers.
“Whereas there’s nonetheless extra to be performed, we’re making progress, and it’s certainly a shared problem.”